ArticleAmerican journal of translational research2025
FOLFOX-HAIC combined with PD-1 inhibitor immunotherapy significantly improves survival in patients with advanced hepatocellular carcinoma.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the effect of FOLFOX-HAIC combined with PD-1 inhibitor immunotherapy on the survival of patients with advanced hepatocellular carcinoma (HCC).
methodThis retrospective study analyzed 137 patients with advanced HCC, of which 71 received FOLFOX-HAIC chemotherapy (control group) and 66 received FOLFOX-HAIC combined with PD-1 inhibitors (research group) between January 2020 and August 2021. Propensity score matching (PSM) was employed to account for confounding variables. Cox regression analysis was utilized to identify independent risk factors that sabotaged patients' survival, and Kaplan-Meier curves were applied to demonstrate patients' overall survival (OS).
resultsA significantly higher disease control rate (DCR) was observed in the research group than that in the control group (77.27% vs. 60.56%, P = 0.035). Prior to PSM analysis, the OS of patients in the research group was calculated to be 25 months, which was significantly higher than the 14 months in the control group (P = 0.015). While post PSM analysis, the median OS turned out to be 27 months in the research group, still significantly higher in comparison to the control group (P = 0.001), whose OS was 14 months. By multivariate analysis, the maximum tumor diameter, Eastern Cooperative Oncology Group Performance Status score, and treatment regimen were identified as independent factors affecting patients' prognosis.
conclusionFOLFOX-HAIC combined with PD-1 inhibitor immunotherapy can significantly prolong the survival in patients with advanced HCC. Apparently, this combined therapy is advantageous at extending patient's survival time in comparison to the use of FOLFOX-HAIC therapy alone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.